PAIA
EW icon

Park Avenue Institutional Advisers’s Edwards Lifesciences EW Stock Holding History

Park Avenue Institutional Advisers’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,077
Closed -$136K – 145
2016
Q2 		$136K Hold
4,077
– – 0.12% 211
2016
Q1 		$120K Sell
4,077
-135
-3% -$3.73K 0.1% 233
2015
Q4 		$111K Sell
4,212
-84
-2% -$2.18K 0.1% 249
2015
Q3 		$102K Sell
4,296
-72
-2% -$1.74K 0.09% 262
2015
Q2 		$104K Buy
+4,368
New +$98.6K 0.08% 275

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Park Avenue Institutional Advisers's EW Position: Q3 2016 in Review

Park Avenue Institutional Advisers sold out of Edwards Lifesciences (EW) in Q3 2016, closing a stake of 4,077 shares — an estimated $136K sold.

Park Avenue Institutional Advisers first reported a position in EW in Q2 2015 and held it in 5 quarters. The position peaked at $136K in Q2 2016. 695 funds tracked by Wall St. Rank hold EW as of Q3 2016.

  • Park Avenue Institutional Advisers reported no remaining Edwards Lifesciences position as of Q3 2016 after selling out during the quarter.
  • Park Avenue Institutional Advisers sold 4,077 Edwards Lifesciences shares in Q3 2016, an estimated $136K.
  • Park Avenue Institutional Advisers first reported a position in Edwards Lifesciences in Q2 2015 and held it in 5 quarters.
  • Park Avenue Institutional Advisers's Edwards Lifesciences position peaked at $136K in Q2 2016.
  • 695 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2016.

Based on Park Avenue Institutional Advisers's 13F filing for Q3 2016, filed 15 Feb 2017.